AGRX AGILE THERAPEUTICS

Agile Therapeutics to Participate in Maxim Group’s Leading Innovators in Women’s Health Virtual Conference

Agile Therapeutics to Participate in Maxim Group’s Leading Innovators in Women’s Health Virtual Conference

PRINCETON, N.J., Aug. 11, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that Al Altomari, Chairman and Chief Executive Officer, will participate in a panel discussion as part of Maxim Group’s M-Vest Virtual Conference Series: Leading Innovators in Women’s Health, beginning at 10:00 a.m. Eastern Time on Thursday, August 13, 2020. The panel will be moderated by Jason McCarthy, PhD, lead biotechnology analyst at Maxim Group.

Webcast Details:

  • Date and Time: Thursday, August 13, 10:00 a.m. Eastern time
  • Registration Link:

About Agile Therapeutics, Inc.

Agile Therapeutics is a women's healthcare company dedicated to fulfilling the unmet health needs of today’s women.  Our product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method.  Our initial product, Twirla®, (levonorgestrel and ethinyl estradiol) transdermal system is a non-daily prescription contraceptive. Twirla is based on our proprietary transdermal patch technology, called Skinfusion®, which is designed to allow drug delivery through the skin. For more information, please visit the company website at . The Company may occasionally disseminate material, nonpublic information on the Company’s website.

Follow Agile on  and Twitter: .

Contact: 

Matt Riley

Head of Investor Relations

EN
11/08/2020

Underlying

AGRXAGILE THERAPEUTICS

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on AGILE THERAPEUTICS

 PRESS RELEASE
Free
AGRX AGILE THERAPEUT...

Agile Therapeutics Inc. Announces Completion of Acquisition by Insud P...

Agile Therapeutics Inc. Announces Completion of Acquisition by Insud Pharma, S.L. Agile Therapeutics has combined with Insud Pharma’s US Subsidiary, Exeltis USA, Inc., expanding an already significant women’s health/contraceptive portfolio Agile Therapeutics Common Shareholders to receive $1.52 per share of common stock Agile common stock will cease to be listed on the OTC QB PRINCETON, N.J., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (“Agile”) (OTCQB: AGRX), a women's healthcare company, today announced the completion of the acquisition of Agile by Insud Pharma, S.L. ...

August 26, 2024 1 EN
 PRESS RELEASE
Free
AGRX AGILE THERAPEUT...

Agile Therapeutics Inc. Announces Definitive Merger Agreement with Ins...

Agile Therapeutics Inc. Announces Definitive Merger Agreement with Insud Pharma, S.L. Agile Therapeutics will combine with Insud Pharma’s US Subsidiary, Exeltis, expanding an already significant Women’s Health/contraceptive portfolio Agile Therapeutics Common Shareholders expected to receive $1.52 per share of common stock – approximately a 356% premium to the closing share price on June 25, 2024 Definitive Merger Agreement is subject to Agile Shareholder Approval. Agile Board is recommending shareholder approval of the Definitive Merger Agreement PRINCETON, N.J., June 26, 2024 (GLOBE...

June 26, 2024 1 EN
 PRESS RELEASE
Free
AGRX AGILE THERAPEUT...

Agile Therapeutics Reports First Quarter 2024 Financial Results and Pr...

Agile Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update First Quarter Net Revenue Increased 58% and Factory Sales Increased 3% from Fourth Quarter 2023 Twirla First Quarter 2024 Demand Rebounded 18% from Fourth Quarter 2023 PRINCETON, N.J., May 15, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Pink: AGRX), a women's healthcare company, today reported financial results for the three months ended March 31, 2024 and provided a corporate update. “We are excited about the start of 2024, which saw a rebound in demand, factory sales and net sa...

May 15, 2024 1 EN
 PRESS RELEASE
Free
AGRX AGILE THERAPEUT...

Agile Therapeutics Reports Fourth Quarter & Full Year 2023 Financial R...

Agile Therapeutics Reports Fourth Quarter & Full Year 2023 Financial Results and Provides Corporate Update Full Year 2023 Net Revenue Increased 80% from 2022 While OPEX Decreased 33% Twirla Demand and Factory Sales Up 121% and 114% Respectively in 2023 vs 2022 Company Completes Pay-Off of Debt Facility in First Quarter 2024 Twirla Demand Expected to Rebound in First Quarter 2024 from Decreased Demand in Fourth Quarter 2023 Management to Host Conference Call Today, Thursday, March 28, 2024 at 8:30 a.m. ET PRINCETON, N.J., March 28, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Pi...

March 28, 2024 1 EN
 PRESS RELEASE
Free
AGRX AGILE THERAPEUT...

Agile Therapeutics Announces Delisting from Nasdaq

Agile Therapeutics Announces Delisting from Nasdaq PRINCETON, N.J., March 25, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX) (“Agile Therapeutics” or the “Company”), a women's healthcare company, today announced that the Company has received a final delisting notice from Nasdaq. The delisting is a result of failure to regain compliance with the minimum stockholders’ equity requirement for continued listing on the Nasdaq Capital Market set forth in Nasdaq Listing Rule 5550(b)(1) requiring companies listed on the Nasdaq Capital Market to maintain stockholder’s equity of a...

March 25, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch